TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic HCV infection prior to study enrollment.~2. Screening laboratory results from the central clinical laboratory indicating HCV genotype 2 or 3 infection only (no mixed genotype).~3. Absence OR presence of cirrhosis.~4. If cirrhotic, need to have compensated cirrhosis and absence of hepatocellular carcinoma (HCC)~Exclusion Criteria:~1. Positive screen for hepatitis B surface antigen or anti-human immunodeficiency virus antibody~2. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse.~3. Current enrollment in another clinical study, previous enrolment in this study, or previous use of any investigational or commercially available anti-HCV therapy (other than interferon, pegIFN, RBV, and or SOF) including previous exposure to telaprevir, boceprevir, ABT-450, or ombitasvir (ABT-267).~4. Subjects without cirrhosis: Any current or past clinical evidence of cirrhosis.~5. Abnormal lab tests.~6. Females who are pregnant or plan to become pregnant or breastfeeding, or males whose partners are pregnant or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (genotype [GT]3, noncirrhotic) (Type: EXPERIMENTAL): Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.
- Arm B (GT3, noncirrhotic) (Type: EXPERIMENTAL): OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily \[BID\]) for 12 weeks.
- Arm C (GT2, noncirrhotic) (Type: EXPERIMENTAL): OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.
- Arm D (GT2, noncirrhotic) (Type: EXPERIMENTAL): OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.
- Arm E (GT3, cirrhotic) (Type: EXPERIMENTAL): OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.
- Arm F (GT3, noncirrhotic) (Type: EXPERIMENTAL): OBV/PTV/r (25/150/100) mg QD and SOF (400 mg QD) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric Bronchial Asthma Patients Aged 6 To 14 Years (At The Beginning Of The Treatment Period)~* The Severity Must Be Mild, Moderate Or Severe, Persistent Bronchial Asthma~* The Patient Must Have Symptoms That Can Be Used As Efficacy Variables (Such As Repeated Coughing And Mild Or Moderate Asthma Attacks) During The Observation Period, And Must Be Using Inhaled Steroids~Exclusion Criteria:~* Patient Using Anti-Asthma Treatment Or Therapy Including corticosteroids Or Oral Anti-Allergic Drugs~* Patient With Complications That Will Impair The Judgment Of Efficacy Of This Drug~* Patient With Convulsive Disorders Such As Epilepsy Or Such A History~* Patient With Liver Disease, Renal Impairment, Heart Disease Or Such Other Complication

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Validation of a Novel Foot Offloading Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 years or older and able to provide informed consent~2. Subjects with foot pain due to forefoot or heel fat pad atrophy or chronic plantar fasciitis as defined by heel pain for greater than 6 months and failed non-surgical therapy~3. Willing and able to comply with follow up examinations~Exclusion Criteria:~1. Concurrent injury to the lower extremity that would effect gait~2. Open foot ulcerations, fractures, or diagnosis of osteomyelitis of the feet~3. Surgical foot intervention in the last 6 months~4. Diagnosis of pregnancy or the intent of the participant to become pregnant during participation in this study~5. Neuropathy~6. Any issue that per the physician's determination would render the patient not appropriate to continue participation in the study (compliance, change in physical status, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PopSole™ offloading device (Type: EXPERIMENTAL): This is an external insole device that fits into a shoe and is reusable for a given subject, not for one-time use. It is comparable to other off-the-shelf insoles readily available and presents minimal risk to the participant during the four weeks of study participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals diagnosed with Idiopathic Pulmonary Fibrosis~2. Chronic cough \> 8 weeks.~3. Daytime cough severity score ≥ 4 on Cough Severity Numerical Rating Scale at screening~Exclusion Criteria:~1. The following conditions are excluded:~   1. Interstitial lung disease (ILD) known to be caused by domestic and occupational environmental exposures.~  2. Interstitial lung disease (ILD) known to be caused by connective tissue disease.~  3. Interstitial lung disease (ILD) known to be caused by drug related toxicity.~      2. Currently on continuous oxygen therapy.~      3. History of substance abuse that, as determined by the Investigator, may interfere with the conduct of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NAL ER then placebo (Type: EXPERIMENTAL): Participants will receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period, followed by a 2 week washout. They will then receive Placebo tablet (matching NAL ER BID) for 3 weeks.
- Placebo then NAL ER (Type: EXPERIMENTAL): Participants will receive Placebo tablet (matching NAL ER BID) for 3 weeks, followed by a 2 week washout. They will then receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Developing World Study for RotaTeq™ (V260-015)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 4 weeks through 12 weeks at Dose 1~* Parent able to understand study procedures and give consent~Exclusion Criteria:~* Clinical evidence of active gastrointestinal disease~* Subjects who are currently or expected to participate in other studies of investigational products during the 6 weeks after receiving the last dose of RotaTeq™/placebo

- Gender: ALL
- Minimum Age: 4 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): RotaTeq™
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active rheumatoid arthritis based on DAS28 score. Patients received the standard therapy (i.e. one or more conventional DMARDs) for at least three months.~Exclusion Criteria:~* Known hypersensitivity to metformin.~* Patients who have a prior diagnosis with diabetes mellitus.~* Patients receive metformin for any other indications.~* Patients with congestive heart failure.~* Patients with a history of myocardial infarction.~* Patients with severe anemia.~* Patients with active infections or other inflammatory diseases.~* Patients receiving biological therapy.~* Pregnancy or lactation.~* Patients with impaired liver functions.~* Patients with impaired kidney functions (serum creatinine concentrations ≥1.5 and ≥1.4 mg/dL in males and females respectively).~* Patients with malignancies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): patients will receive the standard therapy (methotrexate) plus placebo tablets
- Metformin group (Type: EXPERIMENTAL): patients will receive the standard therapy plus 1 g metformin daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be ≥18 years of age and ≤ 65 years~2. Have symptoms consistent with dyspepsia of at least two weeks duration (defined as recurrent pain or discomfort centered in the upper abdomen, often with a relation to meals)~3. Be positive for H. pylori by 13C Urea Breath Test (UBT) and also by fecal antigen test~4. Be informed of the nature of the study and provide written informed consent before any study specific procedures are performed (or have a legally authorized representative sign consent)~Exclusion Criteria:~1. Have alarm symptoms/signs (including unexplained anemia \[iron deficiency), melena / hematemesis, anorexia, dysphagia, jaundice, weight loss)~2. Have taken antibiotics in the 4 weeks prior to screening~3. Have taken bismuth containing medications such as peptobismol in the 4 weeks prior to screening~4. Have a history of any previous esophageal or gastric surgery, except for simple closure of perforated ulcer~5. Have a history of gastric outlet obstruction~6. Have a history of hypersecretory state such as Zollinger-Ellison Syndrome~7. Have a history of gastric cancer~8. Have the presence of active gastric and duodenal ulcers or presence of 3 or more active ulcers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RHB-105 (Type: EXPERIMENTAL): RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule.
- Placebo (Type: PLACEBO_COMPARATOR): Capsules that look like the RHB-105 product but contain no active ingredient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Acute Lymphoblastic Leukemia in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Acute lymphoblastic leukemia excluding known mature B-cell ALL by the presence of any of the following: surface immunoglobulin, L3 morphology, t(8;14) (q24;q32), t(8;22) or t(2;8)~* Age \> 12 months but less than 18 years~Exclusion Criteria:~* Prior therapy except, 1 week of steroids, or emergent radiation therapy to the mediastinum~* Known HIV positive

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Individualized ASP dose (Type: EXPERIMENTAL): None
- Fixed dose ASP (Type: ACTIVE_COMPARATOR): None
- Dexamethasone (Type: EXPERIMENTAL): None
- Prednisone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Oral Caffeine and L-Citrulline Supplementation on Arterial Function in Healthy Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Young healthy males~* Non smoker~* Non endurance trained athlete~* No previous history of cardiovascular disease~Exclusion Criteria:~* Female~* Blood pressure greater than 160/100~* Smoker

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Caffeine (Type: ACTIVE_COMPARATOR): 200 mg caffeine tablet produced by CVS Pharmacy, USA
- Placebo (Type: PLACEBO_COMPARATOR): Placebo pill produced by NOW FOODS, USA
- L-citrulline (Type: EXPERIMENTAL): L-citrulline capsule (750 mg) provided by NOW FOODS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All children and adolescents (5-18 years) with asthma in Tayside (Scotland) known:~* To carry the Arg/Arg-16 genotype and~* Currently on inhaled steroids and~* Inhaled bronchodilators according to need will be telephoned or contacted through home visits to establish if they have had:~  * Any school absences from asthma or~ * Out-of-hours visits to GP/hospital visits or admissions due to asthma over the previous 12 months.~Exclusion Criteria:~* The presence of serious respiratory or multi-system disease (e.g. cystic fibrosis, cancer under current treatment)

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): The active comparator arm consists of Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device as per current inhaled steroid dose plus oral montelukast
- 2 (Type: PLACEBO_COMPARATOR): The placebo comparator arm consists of Seretide® (salmeterol plus equivalent dose of fluticasone) via accuhaler dry powder inhaler device as per current inhaled steroid dose plus placebo for montelukast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Role of Pictorial Asthma Action Plans to Promote Self-management in Rural Youth With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 8-17 years~* new patient (to clinic) with a diagnosis of persistent asthma or an established patient with uncontrolled persistent asthma and a clinical need for a new treatment regimen~* no history of having received a written AAP~* prescribed an inhaled corticosteroid (i.e., daily controller medication).~Exclusion Criteria:~* patients and caregivers who do not use English as their primary language~* has a significant developmental (e.g., autism, intellectual disability) or sensory (e.g., blindness) disorder that would preclude completion of study measures.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Pictorial Asthma Action Plan (Type: EXPERIMENTAL): Young people in the Pictorial Asthma Action Plan (PAAP) arm will receive a PAAP generated by their asthma provider using a software program developed for the study. The PAAP will be personalized according to the young person's gender, race, favorite sport/activity, provider's gender, provider's clinic contact details, and hospital in emergency situations. The PAAP contains minimal text, instead illustrating each participant's asthma regimen using pictures, such as color-coded daily controller and rescue inhalers. Each participant will receive multiple copies of their PAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the PAAP.
- Written Asthma Action Plan (Type: ACTIVE_COMPARATOR): Young people in the Written Asthma Action Plan (WAAP) arm will receive a WAAP generated by their asthma provider using using the National Heart, Lung, and Blood Institute (NHLBI) template. The WAAP will be personalized according to the young person's treatment plan. Each participant will receive multiple copies of their WAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the WAAP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of multiple myeloma~* Have been on zoledronic acid or pamidronate for 1-2 years and therapy must have been initiated for osteolytic lesion, bone fracture, spinal compression, or osteopenia due to multiple myeloma~* Stable renal function~Exclusion Criteria:~* Known sensitivity to bisphosphonates~* Receiving investigational drugs considered not safe for co-administration or have a significant effect on bone turnover~* Current active dental problems~* Had bone marrow transplant or blood stem cell transplant within 2 months before study entry or planned transplant within 2 months following enrollment~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid (Type: EXPERIMENTAL): Participants received 4 milligrams (mg) or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes, every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine N-telopeptide of type 1 collagen (NTx) measurement (greater than or equal to \[≥\] 50 nanomoles per millimoles \[nmol/mmol\] creatinine or \<50 nmol/mmol creatinine, respectively).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion criteria~* Biopsy proven aggressive non-hodgkin's lymphoma~  * Follicular center lymphoma Grade 3.~ * Diffuse large B-cell lymphoma.~ * Mantle cell lymphoma.~ * Transformed lymphoma.~* Relapsed or refractory to previous therapy for lymphoma~* At least one prior combination chemotherapy regime~* Measurable disease on cross sectional imaging that is at least 2 cm in the longest diameter~* Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2~* Willing to follow the pregnancy precautions~Key Exclusion criteria~* Any of the following laboratory abnormalities.~  * Absolute neutrophil count (ANC) \< 1,500 cells/mm\^3 (1.5\*10\^9/L).~ * Platelet count \< 60,000/mm\^3 (60\*10\^9/L).~ * Calculated creatinine clearance of \<50mL/min~ * Serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) or Serum glutamic pyruvic transaminase/Alanine transaminase (SGPT/ALT) 5.0 times upper limit of normal (ULN).~ * Serum total bilirubin \> 2.0 mg/dL (34 µmol/L)/conjugated bilirubin \>0.8mg/dL.~* Subjects who are candidates for and willing to undergo an autologous stem cell transplant.~* History of active Central Nervous System (CNS) lymphoma within the previous 6 months~* History of other malignancies within the past year~* Positive Human immunodeficiency virus (HIV) or active Hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lenalidomide (Type: EXPERIMENTAL): 25 mg oral lenalidomide once daily on Days 1-21 every 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete